SAT0229 Effectiveness of Repeated Courses of Rituximab in RA – Results from the Cererra Collaboration

Background Retreatment with rituximab (RTX) is common clinical practice, although several aspects regarding retreatment, such as frequency, need to be further elucidated. Objectives The aim of this study was to describe the effectiveness of repeated courses of RTX in a large observational cohort of real-life patients with RA. Methods Pooled data from the Collaborating European Registries for Rituximab in RA (CERERRA) project were used. Patients with RA who received at least 4 cycles with RTX were identified and included in the analysis. A covariate-adjusted mixed effects model was fitted to the longitudinal DAS28 for patients with complete covariate information, including country, sex, age, anti-CCP status, number of prior biologics and concomitant DMARD treatment. Results 340 patients met the eligibility criteria for these analyses. At baseline (start of RTX) the mean (SD) age was 53.5 (12.6) years, mean (SD) disease duration 12.1 (8.2) years, 83% were females, 79% RF positive and 74% anti-CCP positive. 60% were treated with corticosteroids and 84% with concomitant DMARD. Patients had failed 2.7 (1.5) prior synthetic DMARDs and 1.1 (1.0) prior biologic DMARDs. The baseline DAS28 was 6.0 (1.4). The mean fixed predicted decrease of DAS28 after the first cycle and after each retreatment (1st, 2nd and 3rd) is shown in figure 1. Significant improvement in DAS28 (p